# Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

> **NCT02975843** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 28 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Asthma

## Interventions

- **DRUG:** Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

## Key facts

- **NCT ID:** NCT02975843
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-21
- **Primary completion:** 2017-03-21
- **Final completion:** 2017-04-11
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975843, "Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02975843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*